- Lafutidine
-
-
2026-07-04
- CAS:118288-08-7
- Purity: 0.99
- Lafutidine
-
-
2026-07-03
- CAS:118288-08-7
- Min. Order: 10g
- Purity: 98.5%min
- Supply Ability: 10kg
- Lafutidine
-
- $38.00
-
2026-04-22
- CAS:118288-08-7
- Purity: 99.96%
- Supply Ability: 10g
|
| | Lafutidine Chemical Properties |
| Melting point | 92.7-94.9° | | Boiling point | 704.2±60.0 °C(Predicted) | | density | 1.252±0.06 g/cm3(Predicted) | | storage temp. | Sealed in dry,Store in freezer, under -20°C | | Water Solubility | Insoluble in water | | solubility | DMF:5.0(Max Conc. mg/mL);11.59(Max Conc. mM)
DMSO:48.67(Max Conc. mg/mL);112.77(Max Conc. mM)
DMSO:PBS (pH 7.2) (1:10):0.09(Max Conc. mg/mL);0.21(Max Conc. mM)
Ethanol:9.0(Max Conc. mg/mL);20.86(Max Conc. mM) | | form | powder to crystal | | pka | 13.13±0.46(Predicted) | | color | White to Orange to Green | | InChI | 1S/C22H29N3O4S/c26-21(18-30(27)17-20-7-6-14-28-20)23-9-2-5-13-29-22-15-19(8-10-24-22)16-25-11-3-1-4-12-25/h2,5-8,10,14-15H,1,3-4,9,11-13,16-18H2,(H,23,26)/b5-2- | | InChIKey | KMZQAVXSMUKBPD-DJWKRKHSSA-N | | SMILES | C(NC/C=C\COC1=NC=CC(CN2CCCCC2)=C1)(=O)CS(CC1=CC=CO1)=O | | CAS DataBase Reference | 118288-08-7(CAS DataBase Reference) |
| Safety Statements | 24/25 | | WGK Germany | WGK 1 | | HS Code | 29349990 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral |
| | Lafutidine Usage And Synthesis |
| Description | Lafutidine is a second generation of H2-receptor antagonist. H2-receptor antagonist can strongly inhibit gastric acid secretion compared with conventional drugs such as antacids. Unlike conventional H2-receptor antagonist, lafutidine inhibits gastric acid secretion during daytime as well as nighttime in clinical studies in humans. Lafutidine also has gastroprotective activity independent of its acid antisecretory efficacy, preventing noxious agent-induced gastric mucosal injury and accelerating the repair process following gastric mucosal damage. It also protects experimentally induced reflux esophagitis, indomethacin-induced intestinal, and dextran sulfate sodium-induced colonic inflammation.
Lafutidine is used for gastric and duodenal ulcers. It is also confirmed that lafutidine can be used as an empiric treatment and superior efficacy for primary care practice patients with dyspepsia.
| | References | [1] Tomohiko Shimatani, Masaki Inoue, Tomoko Kuroiwa, Jing Xu, Masuo Nakamura, Susumu Tazuma, Kazuro Ikawa, Norifumi Morikawa (2006) Lafutidine, a Newly Developed Antiulcer Drug, Elevates Postprandial Intragastric pH and Increases Plasma Calcitonin Gene-Related Peptide and Somatostatin Concentrations in Humans: Comparisons with Famotidine, Digestive Diseases and Sciences, 51, 114-120
[2] Bhupesh Dewan, Nisha Philipose (2011) Lafutidine 10 mg versus Rabeprazole 20 mg in the Treatment of Patients with Heartburn-Dominant Uninvestigated Dyspepsia: A Randomized, Multicentric Trial, Gastroenterology Research and Practice, 2011, Article ID 640685
[3] https://www.drugs.com
| | Description | Lafutidine was launched in Japan for the treatment of gastritis, reflux oesophagitis and
peptic ulcers. It can be prepared in eight steps from 4-(2-tetrahydropyranyloxy)-2(Z)-butenl-
ol. Lafutidine is a potent and longer-acting H2 antagonist compared to other marketed
compounds of its class such as cimetidine and famotidine. In contrast to other
commercially available H2 antagonists, lafutidine also exerts a gastroprotective action
probably via capsaicin-sensitive afferent nerves. It was clinically effective in the treatment
of nonsteroidal antiinflammatory drug-induced ulcer in patients refractory to existing
antiulcer agents. | | Description | Lafutidine is a histamine H2 receptor antagonist with gastroprotective activity. It inhibits histamine-induced cAMP production in CHO cells expressing human histamine H2 receptors when used at a concentration of 10 nM. Intragastric administration of lafutidine (3, 10, and 30 mg/kg) reduces hemorrhagic esophageal lesion size and gastric acid secretion in a rat model of pyloric ligation-induced reflux esophagitis. It prevents 5-fluorouracil-induced intestinal mucositis, diarrhea, and body weight loss in wild-type, but not Trpv1-/- or sensory deafferented, mice when administered at doses ranging from 3 to 30 mg/kg. Lafutidine (10 mg/kg) also reduces indomethacin-induced antral ulcer size in wild-type, but not chemically-deafferented, rats. | | Originator | Fujirebio (Japan) | | Uses | (Z)-2-((Furan-2-ylmethyl)sulfinyl)-n-(4-((3-(piperidin-1-ylmethyl)pyridin-2-yl)oxy)but-2-en-1-yl)acetamide is a Histaminic H2 receptor antagonists in ulcer disease. Also, it is a model compound used to investigate the binding mechanism between antiulcer drugs and human serum albumin (HSA). | | Uses | Second generation histamine H2-receptor antagonist. Antiulcerative | | Uses | Lafutidine, a newly developed histamine H(2)-receptor antagonist, inhibits gastric acid secretion | | Definition | ChEBI: Lafutidine is an organic molecular entity. | | Brand name | Stogar, Protecadin | | References | [1] Y. FUKUSHIMA. Potent and Long-Lasting Action of Lafutidine on the Human Histamine H2 Receptor[J]. Digestion, 2001, 64 1: 155-160. DOI: 10.1159/000048856
[2] KENJI NAGAHAMA. Protective effect of lafutidine, a novel H2-receptor antagonist, on reflux esophagitis in rats through capsaicin-sensitive afferent neurons.[J]. Journal of pharmacological sciences, 2003, 93 1: 55-61. DOI: 10.1254/jphs.93.55
[3] T SANO. Lafutidine, a histamine H2 receptor antagonist with mucosal protective properties, attenuates 5-fluorouracil-induced intestinal mucositis in mice through activation of extrinsic primary afferent neurons.[J]. Journal of Physiology and Pharmacology, 2017, 68 1: 79-90.
[4] S ONODERA. Gastroprotective mechanism of lafutidine, a novel anti-ulcer drug with histamine H2-receptor antagonistic activity.[J]. Arzneimittel-Forschung-Drug Research, 1999, 49 6: 519-526. DOI: 10.1055/s-0031-1300454 |
| | Lafutidine Preparation Products And Raw materials |
|